Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC



Status:Available
Conditions:Lung Cancer, Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/8/2018
Contact:Novartis Pharmaceuticals
Email:Novartis.email@novartis.com
Phone:1-888-669-6682

Use our guide to learn which trials are right for you!

An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity

Novartis-sponsored, open-label, multi-center, interventional ETP to provide LDK378 to
patients with ALK (+)NSCLC, who have been pre-treated with an ALK inhibitor; except in
countries where ALK inhibitors are not approved or available. The protocol will further
evaluate the safety of LDK378 in patients with ALK(+) NSCLC.


Inclusion Criteria (patients eligible for inclusion in this early treatment protocol have
to meet all of the following criteria):

1. Histologically or cytologically confirmed diagnosis of NSCLC that demonstrates ALK
positivity as assessed by approved FISH test (Abbott Molecular Inc), using Vysis
breakapart probes (defined as 15% or more positive tumor cells); or the Ventana IHC
test. If documentation of ALK positivity is not available, the test to confirm ALK
positivity must be performed according to the above criterion, using a new tumor
biopsy obtained prior to the first dose of ETP treatment (LDK378).

2. Stage IIIB or IV NSCLC patient with documented disease progression at enrollment, and
who does not qualify or have access to LDK378 through a clinical trial.

3. Age 18 years or older at the time of informed consent.

4. WHO performance status 0-3.

5. Patients who have been pre-treated with an ALK inhibitor for locally advanced or
metastatic NSCLC. Patients may be enrolled without prior exposure to an ALK inhibitor
in countries where ALK inhibitors are not approved or available. Exposure to prior
chemotherapy is not required.

6. Patients must have recovered from all toxicities related to prior anticancer therapies
to grade ≤ 2 (CTCAE v 4.03), provided that concomitant medication is given prior to
initiation of treatment with LDK378. Exception to this criterion: patients with any
grade of alopecia are allowed to enter the treatment.

7. The following laboratory criteria have been met:

- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

- Hemoglobin (Hgb) ≥ 8 g/dL

- Platelets ≥ 75 x 109/L

- Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN), except for patients
with Gilbert's syndrome who may be included if total bilirubin ≤ 3.0 x ULN and
direct bilirubin ≤ 1.5 x ULN

- Aspartate transaminase (AST) < 3.0 x ULN, except for patients with liver
metastasis, who are only included if AST < 5 x ULN; alanine transaminase (ALT) <
3.0 x ULN, except for patients with liver metastasis, who are only included if
ALT < 5 x ULN.

- Calculated or measured creatinine clearance (CrCL) ≥ 30 mL/min

8. Patient must have the following laboratory values or have the following laboratory
values corrected with supplements to be within normal limits at screening:

- Potassium ≥ LLN

- Magnesium ≥ LLN

- Phosphorus ≥ LLN

- Total calcium (corrected for serum albumin) ≥ LLN

9. Written informed consent for the ETP protocol must be obtained prior to any screening
procedures. If consent cannot be expressed in writing, it must be formally documented
and witnessed, ideally via an independent trusted witness.

10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory
tests and other ETP procedures.

Exclusion Criteria (patients eligible for this ETP must not meet any of the following
criteria):

1. Patients with known hypersensitivity to any of the excipients of LDK378
(microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and
magnesium stearate).

2. Patients with symptomatic CNS metastases who are neurologically unstable or have
required increasing doses of steroids within the 1 week prior to ETP entry to manage
CNS symptoms.

3. Prior therapy with LDK378.

4. The patient is less than 5 half-lives from prior ALK inhibitor or targeted therapy
(for adequate wash-out) without recovery from treatment toxicities to ≤ grade 1 or to
their pretreatment levels.

5. Chemotherapy or an investigational therapy ≤ 3 weeks prior to starting the LDK378
treatment who have not recovered from side effects of such treatment toxicities to ≤
grade 2 or to their pre- treatment toxicities levels, with the exception of liver and
cardiac functions which must be ≤ grade 1.

6. Patients who have received thoracic radiotherapy to lung fields ≤ 4 weeks prior to
starting the study treatment or patients who have not recovered from
radiotherapy-related toxicities. For all other anatomic sites (including radiotherapy
to thoracic vertebrae and ribs) radiotherapy ≤ 2 weeks prior to starting the LDK378
treatment or have not recovered from radiotherapy-related toxicities. Palliative
radiotherapy for bone lesions ≤ 2 weeks prior to starting LDK378 treatment is allowed.

7. Major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks
prior (2 weeks for resection of brain metastases) to starting LDK378 treatment or who
have not recovered from side effects of such procedures. Video-assisted thoracic
surgery (VATS) and mediastinoscopy will not be counted as major surgery, and patients
can be enrolled in the ETP ≥ 2 weeks after the procedure.

8. Presence or history of a malignant disease other than NSCLC that has been diagnosed
and/or required therapy within the past 3 years. Exceptions to this exclusion include
the following: completely resected basal cell and squamous cell skin cancers, and
completely resected carcinoma in situ of any type.

9. Patients with known history of extensive disseminated bilateral interstitial fibrosis
or interstitial lung disease, including a history of pneumonitis, hypersensitivity
pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and clinically
significant radiation pneumonitis (i.e. affecting activities of daily living or
requiring therapeutic intervention).

10. Patient has clinically significant, uncontrolled heart disease and/or recent cardiac
event (within 6 months), such as:

- unstable angina within 6 months prior to screening;

- myocardial infarction within 6 months prior to screening;

- history of documented congestive heart failure (New York Heart Association
functional classification III-IV);

- uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) ≥ 160 mm Hg
and/or Diastolic Blood Pressure (DBP) ≥ 100 mm Hg, with or without
antihypertensive medication -

- initiation or adjustment of antihypertensive medication(s) is allowed prior to
screening;

- ventricular arrhythmias; supraventricular and nodal arrhythmias not controlled
with medication;

- other cardiac arrhythmia not controlled with medication;

- corrected QTc > 450 msec using Fridericia correction on the screening ECG

11. Impaired GI function or GI disease that may alter absorption of LDK378 or inability to
swallow up to five LDK378 capsules daily

12. Ongoing GI adverse events > grade 2 (e.g. nausea, vomiting, or diarrhea) at the start
of the ETP.

13. Receiving medications that meet one of the following criteria and that cannot be
discontinued at least 1 week prior to the start of treatment with LDK378 and for the
duration of the ETP participation (see Appendix 1: Tables 14-1, Table 14-2, Table
14-3, and Table 14-4):

- Medication with a known risk of prolonging the QT interval or inducing Torsades
de Pointes (please refer to
http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm)

- Strong inhibitors or strong inducers of CYP3A4/5 (please refer to
http://medicine.iupui.edu/flockhart/table.htm or
http://www.druginteractioninfo.org)

- Medications with a low therapeutic index that are primarily metabolized by
CYP3A4/5, CYP2C8 and/or CYP2C9 (please refer to
http://medicine.iupui.edu/flockhart/table.htm or
http://www.druginteractioninfo.org)

- Therapeutic doses of warfarin sodium (Coumadin) or any other coumadin-derived
anti-coagulant. Anticoagulants not derived from warfarin are allowed (eg,
dabigatran, rivaroxaban, apixaban).

- Unstable or increasing doses of corticosteroids

- enzyme-inducing anticonvulsive agents

- herbal supplements

14. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
female after conception and until the termination of gestation, confirmed by a
positive hCG laboratory test.

15. Women of child-bearing potential, defined as all women physiologically capable of
becoming pregnant, unless they are using highly effective methods of contraception
during dosing and for 3 months after the last dose of study treatment.

In case of use of oral contraception, women should have been stable on the same pill
for a minimum of 3 months before taking study treatment.

Women are considered post-menopausal and not of child bearing potential if they have
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile
(e.g., age appropriate, history of vasomotor symptoms) or have had surgical bilateral
oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior
to screening. In the case of oophorectomy alone, only when the reproductive status of
the woman has been confirmed by follow up hormone level assessment is she considered
not of child bearing potential.

16. Sexually active males unless they use a condom during intercourse while taking drug
and for 3 months after the last dose of study treatment. Male patients for 3 months
should not father a child in this period. A condom is required to be used also by
vasectomized men in order to prevent delivery of the drug via seminal fluid.
We found this trial at
69
sites
Columbus, Georgia 31901
Principal Investigator: Andrew Pippas
Phone: 706-571-1050
?
mi
from
Columbus, GA
Click here to add this to my saved trials
7000 Fannin St
Houston, Texas 77030
(713) 500-4472
Principal Investigator: Shan Guo
Phone: 713-741-3803
University of Texas Health Science Center at Houston The University of Texas Health Science Center...
?
mi
from
Houston, TX
Click here to add this to my saved trials
8940 N Kendall Dr # 300E
Miami, Florida 33176
Principal Investigator: Paul Kaywin
Phone: 305-595-2141
?
mi
from
Miami, FL
Click here to add this to my saved trials
305 1st Avenue # Dazian 7
New York, New York 10003
(212) 420-2806
Principal Investigator: Ben Levy
Phone: 212-420-4111
Beth Israel Med Ctr The physicians and staff of Mount Sinai Beth Israel's Heart Institute...
?
mi
from
New York, NY
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Ariel Loopez-Chavez
Phone: 503-346-7894
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Christina Baik
Phone: 206-288-2171
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
2950 Cleveland Clinic Blvd.
Weston, Florida 33331
866.293.7866
Principal Investigator: Bruno Bastos
Phone: 954-659-6213
Cleveland Clinic Florida Cleveland Clinic Florida, located in Weston, West Palm Beach, Palm Beach Gardens...
?
mi
from
Weston, FL
Click here to add this to my saved trials
Akron, Ohio 44304
Principal Investigator: Jennifer E. Payne
Phone: 330-375-3000
?
mi
from
Akron, OH
Click here to add this to my saved trials
1200 S Cedar Crest Blvd
Allentown, Pennsylvania 18103
(610) 402-8000
Principal Investigator: Eliot Friedman
Phone: 610-402-9830
Lehigh Valley Hospital At Lehigh Valley Health Network, we continually go the extra mile to...
?
mi
from
Allentown, PA
Click here to add this to my saved trials
Atlanta, Georgia 30308
Principal Investigator: Suchita Pakkala
Phone: 404-712-2587
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Atlanta, Georgia 30318
Principal Investigator: Charles Henderson
Phone: 512-421-4163
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Baltimore, Maryland 21224
Principal Investigator: Rodrigo Erlich
Phone: 410-550-1117
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Birmingham, Alabama 35223
Principal Investigator: James Lasker
Phone: 205-939-7181
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Boston, Massachusetts 02114
Principal Investigator: Alice Shaw
Phone: 617-643-2208
?
mi
from
Boston, MA
Click here to add this to my saved trials
41 Mall Road
Burlington, Massachusetts 1805
781-744-5100
Principal Investigator: Paul Hesketh
Phone: 781-744-2500
Lahey Clinic When Frank Lahey, MD, founded a group practice in 1923, his vision was...
?
mi
from
Burlington, MA
Click here to add this to my saved trials
Caba, Buenos Aires
?
mi
from
Caba,
Click here to add this to my saved trials
Chandler, Arizona 85224
Principal Investigator: Sujith R. Kalmadi
Phone: 480-855-2225
?
mi
from
Chandler, AZ
Click here to add this to my saved trials
Charleston, South Carolina 29425
Principal Investigator: Keisuke Shirai
Phone: 843-792-1415
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Chattanooga, Tennessee 37403
Principal Investigator: Robert Matthew Graham
Phone: +1 423 778 7537
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Principal Investigator: Mary J Fidler
Phone: 312-942-8011
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Chicago, Illinois 60614
Principal Investigator: Jyoti D. Patel
Phone: 312-695-1379
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1400 East Boulder Street
Colorado Springs, Colorado 80909
Principal Investigator: Robert Hoyer
Phone: 719-365-6568
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
2201 Inwood Rd
Dallas, Texas 75235
(214) 645-8300
Principal Investigator: Joan H. Schiller
Phone: 214-645-6488
U.T. Southwestern Medical Center The story of UT Southwestern Medical Center is one of commitment...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Denver, Colorado 80204
Principal Investigator: Ana Oton
Phone: 303-436-5789
?
mi
from
Denver, CO
Click here to add this to my saved trials
Detroit, Michigan 48201
Principal Investigator: Shirish M. Gadgeel
Phone: 313-576-9454
?
mi
from
Detroit, MI
Click here to add this to my saved trials
1500 East Duarte Road
Duarte, California 91010
626-256-HOPE (4673)
Principal Investigator: Marianna Koczywas
Phone: 626-256-4673 Ext. 85013
City of Hope National Medical Center City of Hope is dedicated to making a difference...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Edina, Minnesota 55432
Principal Investigator: Priya Kumar
Phone: 952-836-3645
?
mi
from
Edina, MN
Click here to add this to my saved trials
Fayetteville, Arkansas 72703
Principal Investigator: Eric S Schaefer
Phone: 479-587-1700
?
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Germantown, Tennessee 38138
Principal Investigator: Clyde Jones
Phone: 901-685-5969
?
mi
from
Germantown, TN
Click here to add this to my saved trials
Gettysburg, Pennsylvania 17325
Principal Investigator: Satish Shah
Phone: 717-334-4033
?
mi
from
Gettysburg, PA
Click here to add this to my saved trials
Gilbert, Arizona 85234
Principal Investigator: Klaus Wagner
Phone: 480-256-3333
?
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Goodyear, Arizona 85338
Principal Investigator: Glen Weiss
Phone: 602-358-8400
?
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Goshen, Indiana 46526
Principal Investigator: Ebenezer Kio
Phone: 574-535-2888
?
mi
from
Goshen, IN
Click here to add this to my saved trials
Grand Junction, Colorado 81501
Principal Investigator: Mark Hancock
Phone: 970-298-7125
?
mi
from
Grand Junction, CO
Click here to add this to my saved trials
1800 15th Street
Greeley, Colorado 80631
Principal Investigator: Ariel Soriano
Phone: 970-378-3894
?
mi
from
Greeley, CO
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Principal Investigator: Martin E. Gutierrez
Phone: 201-996-2000
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
Principal Investigator: George R. Blumenschein
Phone: 713-745-3357
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Jackson, Mississippi 39202
Principal Investigator: Bobby L. Graham
Phone: 601-974-5547
?
mi
from
Jackson, MS
Click here to add this to my saved trials
Knoxville, Tennessee 37920
Principal Investigator: Russell F DeVore
Phone: 865-632-5122
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
La Jolla, California 92093
Principal Investigator: Lyudmila Bazhenova
Phone: 858-822-6267
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Lancaster, Pennsylvania 17601
Principal Investigator: H. Peter DeGreen
Phone: 717-291-1313
?
mi
from
Lancaster, PA
Click here to add this to my saved trials
Lincoln, Nebraska 68506
Principal Investigator: Mark Hutchins
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
Long Beach, California 90813
Principal Investigator: Andre Kiem Dian Liem
Phone: +1 562 590 0345
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
Los Angeles, California 90073
Principal Investigator: Fairooz Kabbinavar
Phone: 310-478-3711
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Madison, Wisconsin 53792
(608) 263-2400
Principal Investigator: Ticiana Leal
University of Wisconsin In achievement and prestige, the University of Wisconsin–Madison has long been recognized...
?
mi
from
Madison, WI
Click here to add this to my saved trials
New Brunswick, New Jersey 08901
Principal Investigator: Mark N. Stein
Phone: 732-235-7457
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
330 Washington St #220
Norwich, Connecticut 06360
(860) 886-8362
Principal Investigator: Dennis E. Slater
Phone: 860-886-8362
Eastern Connecticut Hematology and Oncology Associates In 1985 Dr. Dennis Slater moved from Memorial Sloan-Kettering...
?
mi
from
Norwich, CT
Click here to add this to my saved trials
Ogden, Utah 84403
Principal Investigator: Harold Johnson
Phone: 801-398-2836
?
mi
from
Ogden, UT
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73120
Principal Investigator: Jess F. Armor
Phone: 954-659-5579
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Omaha, Nebraska 68106
Principal Investigator: Gamini S Soori
Phone: 402-991-8070
?
mi
from
Omaha, NE
Click here to add this to my saved trials
5721 W 119th St
Overland Park, Kansas 66209
(913) 498-6000
Principal Investigator: Joseph Stilwill
Phone: 913-498-7892
Menorah Medical Center Menorah Medical Center (MMC), a full-service, acute care hospital located on the...
?
mi
from
Overland Park, KS
Click here to add this to my saved trials
Park Ridge, Illinois 60068
Principal Investigator: Navkiranjit Gill
Phone: 866-611-1991
?
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19111
Principal Investigator: Ranee Mehra
Phone: 215-728-3545
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
320 E North Ave
Pittsburgh, Pennsylvania 15212
(412) 359-3131
Principal Investigator: Moses Raj
Phone: 412-359-3802
Allegheny General Hospital At Allegheny General Hospital, our physicians and healthcare staff have earned an...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Principal Investigator: Julian R. Molina
Phone: 507-284-2511
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Rockford, Illinois 61104
Principal Investigator: William Schulz
Phone: 779-696-9400
?
mi
from
Rockford, IL
Click here to add this to my saved trials
Rockville, Maryland 20850
Principal Investigator: Nicholas Farrell
Phone: 301-424-6231
?
mi
from
Rockville, MD
Click here to add this to my saved trials
Salt Lake City, Utah 84112
Principal Investigator: Sunil Sharma
Phone: 801-585-5318
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Santa Rosa, California 95403
Principal Investigator: Ian Anderson
Phone: 707-542-2783
?
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
1959 NE Pacific St
Seattle, Washington 98195
(206) 598-3300
Principal Investigator: Daniel Morgenzstern
Phone: 206-685-1048
University of Washington Medical Center University of Washington Medical Center is one of the nation's...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
615 N Michigan St
South Bend, Indiana 46601
(574) 647-1000
Principal Investigator: Thomas Reid, III
Phone: 574-647-1100
Memorial Hospital of South Bend Memorial Hospital of South Bend is a community-owned, not-for-profit corporation...
?
mi
from
South Bend, IN
Click here to add this to my saved trials
Southington, Connecticut 06489
Principal Investigator: Peter Byeff
Phone: *see various departments*
?
mi
from
Southington, CT
Click here to add this to my saved trials
450 Serra Mall
Stanford, California 94305
(650) 723-2300
Principal Investigator: Heather Ann Wakelee
Phone: 650-725-3973
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
?
mi
from
Stanford, CA
Click here to add this to my saved trials
Topeka, Kansas 66606
Principal Investigator: Daniel Einsphar
Phone: 785-270-4850
?
mi
from
Topeka, KS
Click here to add this to my saved trials
Urbana, Illinois 61801
Principal Investigator: James Egner
Phone: 217-383-6828
?
mi
from
Urbana, IL
Click here to add this to my saved trials
Washington, District of Columbia 20010
Principal Investigator: Suman B. Rao
Phone: 202-877-9163
?
mi
from
Washington,
Click here to add this to my saved trials
Westwood, Kansas 66205
Principal Investigator: Heather Male
Phone: 913-588-0789
?
mi
from
Westwood, KS
Click here to add this to my saved trials
Willow Grove, Pennsylvania 19090
Principal Investigator: Peter Pickens
Phone: 215-706-2034
?
mi
from
Willow Grove, PA
Click here to add this to my saved trials
Ypsilanti, Michigan 48197
Principal Investigator: Philip Stella
Phone: 734-712-5396
?
mi
from
Ypsilanti, MI
Click here to add this to my saved trials